Results · Apr-Jun 2026 · filed 11 Aug 2026
Fermenta Biotech Q1 FY27 results
Sales fell 11% to ₹122 crore from ₹136 crore in Apr-Jun 2025.
Operating profit fell 36% to ₹18.1 crore, an operating margin of 14.8% (down 5.9 points from a year ago).
Net profit fell 56% to ₹9.5 crore from ₹21.6 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +0%, net profit −49%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 121.8 | 136.3 | −11% |
| Operating profit (EBITDA) | 18.1 | 28.2 | −36% |
| Operating margin | 14.8% | 20.7% | −5.9 pts |
| Net profit | 9.5 | 21.6 | −56% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Credit Rating
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 11 Aug 2026Declaration Of Voting Results Of The 74Th Annual General Meeting
- 11 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 11 Aug 2026Shareholder Meeting / Postal Ballot-Outcome of AGM
- 11 Aug 2026Presentation For Shareholders At 74Th Annual General Meeting ('AGM')
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.